Matthew D Peters

US Patent:

7524664, Apr 28, 2009

Filed:

Jun 15, 2004

Appl. No.:

10/869825

Inventors:

Frances H. Arnold - La Cañada CA, US
Matthew W. Peters - Pasadena CA, US
Peter Meinhold - Pasadena CA, US

Assignee:

California Institute of Technology - Pasadena CA

International Classification:

C12N 9/02
C12N 15/00
C12N 1/20
C12P 7/00
C12P 21/04
C07H 21/04
C12Q 1/68
C12Q 1/00
C12Q 1/26

US Classification:

435189, 435 4, 435 6, 435 691, 435 711, 435 25, 435132, 435440, 4352523, 4353201, 536 232

Abstract:

Cytochrome P450 BM-3 from was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-positio to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with , where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.

US Patent:

7863030, Jan 4, 2011

Filed:

Apr 15, 2009

Appl. No.:

12/424454

Inventors:

Frances H Arnold - La Canada CA, US
Matthew W Peters - Pasadena CA, US
Peter Meinhold - Pasadena CA, US

Assignee:

The California Institute of Technology - Pasadena CA

International Classification:

C12N 9/02
C12N 15/00
C12N 1/20
C12P 7/00
C12P 21/04
C07H 21/04
C12Q 1/68
C12Q 1/00
C12Q 1/26

US Classification:

435189, 435 4, 435 6, 435 691, 435 711, 435 25, 435132, 435440, 4352523, 4353201, 536 232

Abstract:

Cytochrome P450 BM-3 from was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-positio to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with , where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.

US Patent:

8343744, Jan 1, 2013

Filed:

Jan 3, 2011

Appl. No.:

12/983841

Inventors:

Frances H Arnold - La Canada CA, US
Matthew W Peters - Pasadena CA, US
Peter Meinhold - Pasadena CA, US

Assignee:

The California Institute of Technology - Pasadena CA

International Classification:

C12N 9/02
C12N 15/00
C12P 7/00
C12P 21/06
C12P 21/04
C07H 21/04

US Classification:

435189, 435 711, 435440, 435132, 435 691, 536 232

Abstract:

Cytochrome P450 BM-3 from was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with , where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.

US Patent:

20080057577, Mar 6, 2008

Filed:

Apr 6, 2007

Appl. No.:

11/697404

Inventors:

Frances Arnold - Pasadena CA, US
Peter Meinhold - Pasadena CA, US
Matthew Peters - Pasadena CA, US
Rudi Fasan - Brea CA, US
Mike Chen - Pasadena CA, US

Assignee:

California Institute of Technology - Pasadena CA

International Classification:

C07K 14/32
C07K 1/107
C12N 1/19
C12N 1/21
C12N 5/10

US Classification:

435348000, 435252300, 435254200, 435325000, 530350000, 530402000, 536023700

Abstract:

This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.

US Patent:

20100062505, Mar 11, 2010

Filed:

Dec 21, 2007

Appl. No.:

11/963542

Inventors:

Uvini Gunawardena - Pasadena CA, US
Peter Meinhold - Pasadena CA, US
Matthew W. Peters - Pasadena CA, US
Jun Urano - Culver City CA, US
Reid M. Renny Feldman - San Marino CA, US

Assignee:

Gevo, Inc. - Pasadena CA

International Classification:

C12P 7/16
C12N 1/18
C12N 1/15

US Classification:

435160, 4352542, 43525421

Abstract:

There are disclosed metabolically-engineered yeast and methods of producing n-butanol. In an embodiment, metabolically-engineered yeast is capable of metabolizing a carbon source to produce n-butanol, at least one pathway produces increased cytosolic acetyl-CoA relative to cytosolic acetyl-CoA produced by a wild-type yeast, and at least one heterologous gene encodes and expresses at least one enzyme for a metabolic pathway capable of utilizing NADH to convert acetyl-CoA to n-butanol. In another embodiment, a method of producing n-butanol includes (a) providing metabolically-engineered yeast capable of metabolizing a carbon source to produce n-butanol, at least one pathway produces increased cytosolic acetyl-CoA relative to cytosolic acetyl-CoA produced by a wild-type yeast, and at least one heterologous gene encodes and expresses at least one enzyme for a metabolic pathway utilizing NADH to convert acetyl-CoA to n-butanol; and (b) culturing the yeast to produce n-butanol. Other embodiments are also disclosed.

US Patent:

20110287500, Nov 24, 2011

Filed:

Jul 5, 2011

Appl. No.:

13/176452

Inventors:

Jun URANO - Irvine CA, US
Catherine Asleson Dundon - Englewood CO, US
Peter Meinhold - Denver CO, US
Reid M. Renny Feldman - San Francisco CA, US
Aristos Aristidou - Highlands Ranch CO, US
Andrew Hawkins - Parker CO, US
Thomas Buelter - Denver CO, US
Matthew Peters - Highlands Ranch CO, US
Doug Lies - Parker CO, US
Ruth Berry - Englewood CO, US
Ishmeet Kalra - Englewood CO, US

Assignee:

GEVO, INC. - Englewood CO

International Classification:

C12P 7/16
C12N 1/19

US Classification:

435160, 4352542, 43525421

Abstract:

The present invention provides recombinant microorganisms comprising isobutanol producing metabolic pathway with at least one isobutanol pathway enzyme localized in the cytosol, wherein said recombinant microorganism is selected to produce isobutanol from a carbon source. Methods of using said recombinant microorganisms to produce isobutanol are also provided. In various aspects of the invention, the recombinant microorganisms may comprise a cytosolically active isobutanol pathway enzymes. In some embodiments, the invention provides mutated, modified, and/or chimeric isobutanol pathway enzymes with cytosolic activity. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.

US Patent:

20120288910, Nov 15, 2012

Filed:

Jun 20, 2012

Appl. No.:

13/528106

Inventors:

Jun Urano - Irvine CA, US
Catherine Asleson Dundon - Englewood CO, US
Peter Meinhold - Denver CO, US
Reid M. Renny Feldman - San Francisco CA, US
Aristos Aristidou - Englewood CO, US
Andrew Hawkins - Parker CO, US
Thomas Buelter - Denver CO, US
Matthew Peters - Highlands Ranch CO, US
Doug Lies - Parker CO, US
Christopher Smith - Englewood CO, US
Lynne H. Albert - Englewood CO, US

Assignee:

Gevo, Inc. - Englewood CO

International Classification:

C12P 7/16
C12N 1/19

US Classification:

435160, 4352542, 43525421, 43525423, 43525422

Abstract:

The present invention is directed to recombinant microorganisms comprising one or more dihydroxyacid dehydratase (DHAD)-requiring biosynthetic pathways and methods of using said recombinant microorganisms to produce beneficial metabolites derived from said DHAD-requiring biosynthetic pathways. In various aspects of the invention, the recombinant microorganisms may be engineered to overexpress one or more polynucleotides encoding one or more Aft proteins or homologs thereof. In some embodiments, the recombinant microorganisms may comprise a cytosolically localized DHAD enzyme. In additional embodiments, the recombinant microorganisms may comprise a mitochondrially localized DHAD enzyme. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the , Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.

US Patent:

20130273626, Oct 17, 2013

Filed:

Nov 9, 2012

Appl. No.:

13/673977

Inventors:

The California Institute of Technology - , US
Matthew W. Peters - Pasadena CA, US
Peter Meinhold - Pasadena CA, US

International Classification:

C12N 9/00

US Classification:

435157, 435189

Abstract:

Cytochrome P450 BM-3 from was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-positio to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with , where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.